Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants.

Abstract excerpt

PURPOSE: Fluoropyrimidine (FP) chemotherapy can cause life-threatening toxicity. Four DPYD polymorphisms (DPYD*2A, *13, p.Asp949Val, and HapB3) are most well established to increase FP toxicity risk. This study aimed to identify additional DPYD polymorphisms that increase FP severe toxicity. EXPERIMENTAL DESIGN: Adult patients treated with standard doses of systemic FP (5-fluorouracil/capecitabine) for any tumor...

Topics

Join the communities discussing this publication.

• Antimetabolites, Antineoplastic
• Antineoplastic Combined Chemotherapy Protocols
• Capecitabine
• Dihydrouracil Dehydrogenase (NADP)